Apologies for fragmented post.
The clinical results from the recent trials do provide evidence of the pre - post clinical findings (impressive and significant improvements achieved with the DURAVR). The clinical results also show superiority over the competitors products...specifically, the mechanical readings - area of valve and pressure gradient.
The cited article (sample of 80 in two groups - mechanical v bioprosthetic valves) highlited a difference between the two......particularly with the exercise tollerence results......the patients recieving the mechanical valve achieved significant improvements in the 6 minute walk test, yet the bioprosthetic valve shows no improvement.
Perhaps this is another area of superiority our product has - the bioprosthetic valve space.
- Forums
- ASX - By Stock
- AVR
- Ann: AGM Chairman Address and CEO Presentation
Ann: AGM Chairman Address and CEO Presentation, page-26
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.31 |
Change
0.000(0.00%) |
Mkt cap ! $351.9M |
Open | High | Low | Value | Volume |
$18.30 | $19.00 | $18.00 | $363.4K | 19.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 500 | $18.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.50 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 500 | 18.130 |
1 | 300 | 18.110 |
1 | 50 | 18.080 |
1 | 200 | 18.050 |
1 | 1000 | 18.000 |
Price($) | Vol. | No. |
---|---|---|
18.500 | 1000 | 1 |
19.000 | 438 | 1 |
19.290 | 325 | 1 |
19.800 | 264 | 1 |
19.870 | 202 | 1 |
Last trade - 15.59pm 01/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online